New vaccine combined with existing immunotherapy could effectively fight melanoma, study finds

recently, researchers from the Sprees Institute in San Diego, in collaboration with experts from other institutions, have developed a new vaccine that, in combination with existing immunotherapy treatments, not only effectively fights melanoma, but also prevents recurrence after treatmentresearchers tested three different treatments in a mouse model of a malignant melanomaAll the mice received cancer immunotherapy against PD-L1 antibodies, but in addition, they received different vaccine variantsProfessor Boger and his team divided the mice into three groups: one subcutaneous injection of olyssin, one subcutaneous injection of ovary protein plus a molecule called Diprovocim, and the third group of ovary proteins and another adjunic alumDiprovocim induces cytokines (TNF and IL6) in human and mouse cells, and the production of TNF is dose-dependentIn human THP-1 cells and peripheral blood mononucleosis, EC50 reached 110pM and 875pM, respectively, and in mice primary celiac macrophages and bone-derived DC cells, EC50 reached 1.3pM and 6.7nM, respectivelythe researchers analyzed the components of TLR in(wild and defective mice), and found that Diprovocim was targeted at TLR1/TLR2, which activates the downstream MAPK and NF-B signaling pathwaysresearchers found that eight mice with both pheopaprotein and Diprovocim were treated with anti-PD-L1 antibodies, with a 100 percent survival rate over 54 daysby contrast, rodents receiving immunotherapy and egg white protein did not surviveThose who received the anti-PD-L1 antibody and alum vaccine had a 25 percent survival rate over the same period